Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials
Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer. 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fract...
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. The HYPO-RT-PC trial was d...
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
German Hodgkin Study Group HD17 trial investigated whether radiotherapy could be omitted without loss of efficacy in patients with early-stage unfavou...
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
PALLAS is an ongoing multicentre, open-label, randomized, phase 3 study that enrolled patients at 406 cancer centers in 21 countries. 3-year invasive...
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC) The most common...
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial
The SMART protocol consists of a short accelerated course of radiotherapy followed by extrapleural pneumonectomy. Patients received 25 Gy in five dail...
Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study
In-depth analyses of the global demand for cancer surgery and optimal workforce requirements are needed to plan service providers. The number of cance...
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival i...